0001179929-21-000166.txt : 20211027 0001179929-21-000166.hdr.sgml : 20211027 20211027162315 ACCESSION NUMBER: 0001179929-21-000166 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211027 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211027 DATE AS OF CHANGE: 20211027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLINA HEALTHCARE, INC. CENTRAL INDEX KEY: 0001179929 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 134204626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31719 FILM NUMBER: 211353074 BUSINESS ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 BUSINESS PHONE: 5624353666 MAIL ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 FORMER COMPANY: FORMER CONFORMED NAME: MOLINA HEALTHCARE INC DATE OF NAME CHANGE: 20020812 8-K 1 moh-20211027.htm 8-K moh-20211027
0001179929false00011799292021-10-272021-10-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
Current Report
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2021 (October 27, 2021)
______________
MOLINA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware1-3171913-4204626
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
______________
200 Oceangate, Suite 100,Long Beach,California90802
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (562) 435-3666
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value MOHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.



Item 2.02.    Results of Operations and Financial Condition.
On October 27, 2021, Molina Healthcare, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2021, and the Company’s reaffirmed full year 2021 earnings guidance. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the website cited in the press release is not part of this report.
Note: The information in this Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits.
(d)     Exhibits:
Exhibit No.Description
99.1
104
Cover Page information from Molina Healthcare, Inc.’s Current Report on Form 8-K filed on October 27, 2021 formatted in iXBRL (Inline Extensible Business Reporting Language).



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLINA HEALTHCARE, INC.
Date:
October 27, 2021
By:
/s/ Jeff D. Barlow
Jeff D. Barlow
Chief Legal Officer and Secretary


EX-99.1 2 moh3q21_er.htm EX-99.1 Document
molinaa03a01a01a17.jpg
News Release
Investor Contact: Joseph Krocheski, Joseph.Krocheski@molinahealthcare.com, 562-951-8382
Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com, 562-951-1588
Molina Healthcare Reports Third Quarter 2021 Financial Results
Reaffirms Full Year 2021 Earnings Guidance
Long Beach, Calif, October 27, 2021 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported third quarter of 2021 GAAP earnings per diluted share of $2.46 and adjusted earnings per diluted share of $2.83. Financial results are summarized below:
Quarter endedNine months ended
September 30,
 September 30,
 2021202020212020
(In millions, except per-share results)
Premium Revenue$6,800$4,768$19,689$13,444
Total Revenue$7,040$5,021$20,362$14,188
GAAP:
Net Income$143$185$556$639
EPS – Diluted$2.46$3.10$9.51$10.65
Medical Care Ratio (MCR)88.9%85.9%88.1%84.9%
G&A Ratio7.5%7.3%7.3%7.3%
After-tax Margin2.0%3.7%2.7%4.5%
Adjusted:
Net Income $164$201$623$670
EPS – Diluted$2.83$3.36$10.66$11.15
G&A Ratio7.3%7.3%7.1%7.2%
After-tax Margin2.3%4.0%3.1%4.7%
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

Quarter Highlights
GAAP net income for the third quarter of 2021 was $143 million, or $2.46 per diluted share.
Adjusted net income for the third quarter of 2021 was $164 million, or $2.83 per diluted share.
As of September 30, 2021, the Company served approximately 4.8 million members, an increase of 805,000 members, or 20%, compared to September 30, 2020.
Premium revenue was approximately $6.8 billion for the third quarter of 2021, an increase of 43% compared to the third quarter of 2020.
The net effect of COVID decreased net income by approximately $1.00 per diluted share in the third quarter of 2021.
The Company increased its full year 2021 premium revenue guidance to no less than $26.5 billion.
The Company reaffirmed its full year 2021 adjusted earnings guidance of no less than $13.25 per diluted share.

-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 2
October 27, 2021
“We are pleased with our third quarter and year-to-date performance. With the backdrop of a continuing pandemic, we executed well, delivered solid operating earnings, and continued to drive our growth strategy,” said Joseph Zubretsky, president and CEO of Molina Healthcare. “The Nevada contract award and the AgeWell acquisition reflect that the components of our growth engine are well established and working.”

New York Acquisitions
On October 7, 2021, the Company announced that it has entered into a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million.
On October 25, 2021, the Company announced the closing of its acquisition of Affinity Health Plan.

Premium Revenue
Premium revenue was approximately $6.8 billion for the third quarter of 2021, an increase of 43% compared to the third quarter of 2020. The higher premium revenue reflects increased organic membership in all lines of business, along with the impact of acquisitions.

Net Income
Net income for the third quarter was $143 million, or $2.46 per diluted share, compared to $185 million, or $3.10 per diluted share, in the third quarter of 2020. Adjusted net income for the third quarter was $164 million, or $2.83 per diluted share, compared to $201 million, or $3.36 per diluted share, in the third quarter of 2020.
The year-over-year comparison reflects the negative impact from the net effect of COVID in the third quarter of 2021. In contrast, the prior year third quarter was positively impacted by the net effect of COVID.
Net income for the nine months ended September 30, 2021 was $556 million, or $9.51 per diluted share, compared to $639 million, or $10.65 per diluted share, in the nine months ended September 30, 2020. Adjusted net income for the nine months ended September 30, 2021 was $623 million, or $10.66 per diluted share, compared to $670 million, or $11.15 per diluted share, in the nine months ended September 30, 2020.

Medical Care Ratio
The consolidated MCR for the third quarter was 88.9%, compared to 85.9% in the third quarter of 2020. The net effect of COVID increased the consolidated MCR by approximately 110 basis points and impacted all three lines of business. In the prior year, the net effect of COVID was negligible to slightly positive.
A year-over-year comparison is less meaningful than it would be in a typical year due to pandemic related effects. Due to those anomalous effects, a sequential comparison of MCR is more relevant.
On a sequential basis, the consolidated MCR for the third quarter was 88.9%, compared to 88.4% in the second quarter of 2021. The net effect of COVID increased the consolidated MCR by approximately 110 basis points in the second and third quarters of 2021 and was negligible in the first quarter of 2021.
The Medicaid MCR increased to 89.6% in the third quarter of 2021 compared to 89.0% in the second quarter of 2021. The increase in the MCR was primarily due to an increase in the net effect of COVID.
-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 3
October 27, 2021
The Medicare MCR decreased to 82.8% in the third quarter of 2021 compared to 87.6% in the second quarter of 2021. The decrease in the MCR was primarily due to the lower negative net effect of COVID among our Medicare members.
The Marketplace MCR increased to 91.3% in the third quarter of 2021 compared to 84.8% in the second quarter of 2021. The increase in the MCR was primarily due to the higher net effect of COVID, normal seasonality, and non-COVID utilization by Special Enrollment Period members.

General and Administrative Expense Ratio
The G&A ratio for the third quarter was 7.5%, compared to 7.3% for the third quarter of 2020. The adjusted G&A ratio for the third quarter was 7.3% and was consistent with the third quarter of 2020 reflecting disciplined cost management, and growth investments.

Balance Sheet
Cash and investments at the parent company amounted to $703 million as of September 30, 2021, compared to $644 million as of December 31, 2020. The increase was due to dividends received from the regulated health plan subsidiaries in the quarter.
In September 2021, the Company’s Board of Directors authorized a stock repurchase program of up to $500 million and continuing through December 31, 2022. This program supersedes the stock repurchase program approved by our Board in September 2020. As of October 27, 2021, no shares have been purchased under this program.

Cash Flow
Operating cash flow for the nine months ended September 30, 2021 amounted to $1.5 billion, and was higher compared to the nine months ended September 30, 2020, primarily due to growth in operations and the net impact of timing differences in governmental receivables and payables.

2021 Guidance
The Company expects its full year 2021 total revenue to be no less than $27.5 billion, an increase of approximately 42% from its full year 2020.
Premium revenue for the full year 2021 is expected to be no less than $26.5 billion, an increase of approximately 45% from the full year 2020.
The Company reaffirmed its full year 2021 adjusted earnings per share guidance to be no less than $13.25 per share.
Guidance reflects:
The continuation of the Public Health Emergency period, through mid-January, 2022 and the associated pause on Medicaid membership redeterminations;
Underlying outperformance;
An offset caused by the estimated net effect of COVID which is expected to be approximately $3.00 per share for the full year 2021; and
Continued caution in forecasting utilization trends for the remaining three months of the year due to the COVID pandemic.
The impact of the Cigna Texas membership acquisition is not included in guidance. The Cigna Texas membership acquisition is expected to close in January of 2022.
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 4
October 27, 2021
Conference Call
Management is hosting a conference call and webcast to discuss Molina Healthcare’s third quarter 2021 results at 8:00 a.m. Eastern Time on Thursday, October 28, 2021. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 5108692. A telephonic replay of the conference call will be available through Thursday, November 11, 2021, by dialing (877) 344-7529 and entering confirmation number 10160042. A live audio broadcast of this conference call will be available on Molina Healthcare’s website, molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Through its locally operated health plans, Molina Healthcare served approximately 4.8 million members as of September 30, 2021. For more information about Molina Healthcare, please visit molinahealthcare.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements regarding its 2021 guidance, as well as its plans and expectations regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which is on file with the SEC, and also in its Quarterly Report on Form 10-Q for the period ended September 30, 2021, which the Company expects to file on or about October 28, 2021.
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of October 27, 2021, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.
-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 5
October 27, 2021
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended
Nine Months Ended
 September 30,September 30,
 2021202020212020
 (In millions, except per-share amounts)
Revenue:
Premium revenue$6,800 $4,768 $19,689 $13,444 
Premium tax revenue 204 170 576 477 
Health insurer fees reimbursed— 69 — 206 
Investment income 20 10 39 48 
Other revenue16 58 13 
Total revenue7,040 5,021 20,362 14,188 
Operating expenses:
Medical care costs6,049 4,098 17,342 11,412 
General and administrative expenses532 368 1,489 1,030 
Premium tax expenses204 170 576 477 
Health insurer fees— 70 — 209 
Depreciation and amortization32 23 96 64 
Other30 
Total operating expenses6,819 4,732 19,533 13,201 
Operating income221 289 829 987 
Other expenses, net:
Interest expense30 27 90 72 
Other expense, net— — — 
Total other expenses, net30 27 90 77 
Income before income tax expense
191 262 739 910 
Income tax expense48 77 183 271 
Net income$143 $185 $556 $639 
Net income per share – Diluted$2.46 $3.10 $9.51 $10.65 
Diluted weighted average shares outstanding
58.5 59.6 58.5 60.0 
Operating Statistics:
Medical care ratio88.9 %85.9 %88.1 %84.9 %
G&A ratio7.5 %7.3 %7.3 %7.3 %
Premium tax ratio2.9 %3.4 %2.8 %3.4 %
Effective income tax rate24.8 %29.5 %24.7 %29.8 %
After-tax margin2.0 %3.7 %2.7 %4.5 %

-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 6
October 27, 2021
MOLINA HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
September 30,December 31,
20212020
Unaudited
(Dollars in millions,
except per-share amounts)
ASSETS
Current assets:
Cash and cash equivalents$4,357 $4,154 
Investments2,900 1,875 
Receivables1,912 1,672 
Prepaid expenses and other current assets197 175 
Total current assets9,366 7,876 
Property, equipment, and capitalized software, net385 391 
Goodwill and intangible assets, net915 941 
Restricted investments156 136 
Deferred income taxes 83 69 
Other assets128 119 
Total assets$11,033 $9,532 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable$3,191 $2,696 
Amounts due government agencies 2,081 1,253 
Accounts payable, accrued liabilities and other797 641 
Deferred revenue375 
Total current liabilities6,070 4,965 
Long-term debt2,130 2,127 
Finance lease liabilities220 225 
Other long-term liabilities95 119 
Total liabilities8,515 7,436 
Stockholders’ equity:
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September 30, 2021, and 59 million shares at December 31, 2020
— — 
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
— — 
Additional paid-in capital205 199 
Accumulated other comprehensive income17 37 
Retained earnings2,296 1,860 
Total stockholders’ equity2,518 2,096 
Total liabilities and stockholders’ equity$11,033 $9,532 
-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 7
October 27, 2021
MOLINA HEALTHCARE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended
September 30,
20212020
(in millions)
Operating activities:
Net income$556 $639 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization96 64 
Deferred income taxes(8)(3)
Share-based compensation
49 43 
Loss on debt repayment— 
Other, net
Changes in operating assets and liabilities:
Receivables(247)(369)
Prepaid expenses and other current assets(43)(98)
Medical claims and benefits payable522 431 
Amounts due government agencies 810 (24)
Accounts payable, accrued liabilities and other129 63 
Deferred revenue(374)(188)
Income taxes23 34 
Net cash provided by operating activities
1,522 599 
Investing activities:
Purchases of investments(2,018)(670)
Proceeds from sales and maturities of investments
965 891 
Purchases of property, equipment, and capitalized software
(56)(64)
Net cash paid in business combinations— (62)
Other, net
Net cash (used in) provided by investing activities(1,106)98 
Financing activities:
Common stock purchases
(128)(453)
Common stock withheld to settle employee tax obligations(52)(8)
Contingent consideration liabilities settled(20)— 
Proceeds from senior notes offering, net of issuance costs— 789 
Repayment of term loan facility— (600)
Proceeds from borrowings under term loan facility— 380 
Other, net (4)(47)
Net cash (used in) provided by financing activities(204)61 
Net increase in cash, cash equivalents, and restricted cash and cash equivalents212 758 
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period
4,223 2,508 
Cash, cash equivalents, and restricted cash and cash equivalents at end of period
$4,435 $3,266 
-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 8
October 27, 2021
MOLINA HEALTHCARE, INC.
UNAUDITED SEGMENT DATA
(Dollars in millions)

September 30,December 31,September 30,
2021 (1)
2020
2020
Ending Membership by Segment:
Medicaid3,981,000 3,599,000 3,595,000 
Medicare138,000 115,000 113,000 
Marketplace719,000 318,000 325,000 
Total4,838,000 4,032,000 4,033,000 
(1)Approximately 200,000 members, from the Magellan Complete Care acquisition that closed on December 31, 2020, are included in the totals as of September 30, 2021, but not in prior periods.


Three Months Ended June 30,
20212020
Premium RevenueMedical
Margin
MCR (1)
Premium RevenueMedical
Margin
MCR (1)
Medicaid$5,034 $551 89.0 %$3,375 $553 83.6 %
Medicare814 101 87.6 630 125 80.0 
Marketplace735 112 84.8 367 96 74.0 
Consolidated$6,583 $764 88.4 %$4,372 $774 82.3 %
Three Months Ended September 30,
20212020
Premium RevenueMedical
Margin
MCR (1)
Premium RevenueMedical
Margin
MCR (1)
Medicaid $5,146 $532 89.6 %$3,754 $509 86.4 %
Medicare 875 151 82.8 632 91 85.6 
Marketplace779 68 91.3 382 70 81.6 
Consolidated$6,800 $751 88.9 %$4,768 $670 85.9 %
Nine Months Ended September 30,
20212020
Premium RevenueMedical
Margin
MCR (1)
Premium RevenueMedical
Margin
MCR (1)
Medicaid $15,020 $1,687 88.8 %$10,415 $1,427 86.3 %
Medicare 2,488 329 86.8 1,896 333 82.4 
Marketplace2,181 331 84.8 1,133 272 76.0 
Consolidated$19,689 $2,347 88.1 %$13,444 $2,032 84.9 %
(1)The MCR represents medical costs as a percentage of premium revenue.

-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 9
October 27, 2021
MOLINA HEALTHCARE, INC.
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)

The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
Nine Months Ended
September 30,
20212020
Unaudited
Medical claims and benefits payable, beginning balance
$2,696 $1,854 
Components of medical care costs related to:
Current year17,558 11,478 
Prior year(216)(66)
Total medical care costs17,342 11,412 
Payments for medical care costs related to:
Current year14,880 9,500 
Prior year2,008 1,527 
Total paid16,888 11,027 
Change in acquired balances(27)— 
Change in non-risk and other provider payables68 50 
Medical claims and benefits payable, ending balance
$3,191 $2,289 
Days in claims payable, fee for service (1)
49 52 
__________________
(1)Claims payable includes primarily claims incurred but not paid, or IBNP. It also includes certain fee-for-service payables reported in medical claims and benefits payable amounting to $148 million and $79 million, as of September 30, 2021, and 2020, respectively.

-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 10
October 27, 2021
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)

The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted after-tax margin represents adjusted net income, divided by total revenue.
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
AmountPer Diluted ShareAmountPer Diluted ShareAmountPer Diluted ShareAmountPer Diluted Share
Net income
$143 $2.46 $185 $3.10 $556 $9.51 $639 $10.65 
Adjustments:
Acquisition-related expenses (1)
17 0.28 0.07 44 0.75 0.06 
Amortization of intangible assets
11 0.20 0.06 35 0.60 12 0.19 
Loss on debt repayment— — — — — — 0.08 
Other (2)
— — 13 0.21 0.16 19 0.32 
Subtotal, adjustments
28 0.48 21 0.34 88 1.51 40 0.65 
Income tax effect
(7)(0.11)(5)(0.08)(21)(0.36)(9)(0.15)
Adjustments, net of tax
21 0.37 16 0.26 67 1.15 31 0.50 
Adjusted net income
$164 $2.83 $201 $3.36 $623 $10.66 $670 $11.15 
__________________
(1)Beginning in the third quarter of 2020, reflects non-recurring costs associated with acquisitions, including various transaction and integration costs.
(2)The nine months ended September 30, 2021 includes change in premium deficiency reserves, loss on sale of property, and restructuring costs. The nine months ended September 30, 2020 includes premium deficiency reserves, and restructuring costs.

-MORE-

Molina Healthcare, Inc. Announces Third Quarter 2021 Results
Page 11
October 27, 2021
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
2021 GUIDANCE


Net income per diluted share (1)
$11.61 
Adjustments:
Acquisition-related expenses
1.18 
Amortization of intangible assets
0.81 
Other 0.16 
Subtotal, adjustments
2.15 
Income tax effect (2)
(0.51)
Adjustments, net of tax
1.64 
Adjusted net income per diluted share
$13.25 
__________________
(1)Computations assume approximately 58.6 million diluted weighted average shares outstanding.
(2)Income tax effect calculated at the statutory tax rate of 23.8%.
-END-
EX-101.SCH 3 moh-20211027.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 moh-20211027_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 5 moh-20211027_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 molinaa03a01a01a17.jpg begin 644 molinaa03a01a01a17.jpg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end XML 7 moh-20211027_htm.xml IDEA: XBRL DOCUMENT 0001179929 2021-10-27 2021-10-27 0001179929 false 8-K 2021-10-27 MOLINA HEALTHCARE, INC. DE 1-31719 13-4204626 200 Oceangate, Suite 100, Long Beach, CA 90802 562 435-3666 false false false false Common Stock, $0.001 Par Value MOH NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page Document
Oct. 27, 2021
Cover [Abstract]  
Entity Central Index Key 0001179929
Document Type 8-K
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, $0.001 Par Value
Entity Incorporation, State or Country Code DE
Entity File Number 1-31719
Entity Tax Identification Number 13-4204626
Trading Symbol MOH
Security Exchange Name NYSE
Document Period End Date Oct. 27, 2021
Entity Registrant Name MOLINA HEALTHCARE, INC.
City Area Code 562
Local Phone Number 435-3666
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amendment Flag false
Entity Address, Address Line One 200 Oceangate, Suite 100,
Entity Address, City or Town Long Beach,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90802
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"6U/;7P?M.0$ # " / M " 440 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #G@EM3 M)!Z;HJT #X 0 &@ @ &K$0 >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " #G@EM399!YDAD! #/ P $P M @ &0$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( #:$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Document Sheet http://www.molinahealthcare.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports moh-20211027.htm moh-20211027.xsd moh-20211027_lab.xml moh-20211027_pre.xml moh3q21_er.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "moh-20211027.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "moh-20211027.htm" ] }, "labelLink": { "local": [ "moh-20211027_lab.xml" ] }, "presentationLink": { "local": [ "moh-20211027_pre.xml" ] }, "schema": { "local": [ "moh-20211027.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "moh", "nsuri": "http://www.molinahealthcare.com/20211027", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20211027.htm", "contextRef": "i0428ab4008e34635848a1f62e3cfec19_D20211027-20211027", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Document", "role": "http://www.molinahealthcare.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20211027.htm", "contextRef": "i0428ab4008e34635848a1f62e3cfec19_D20211027-20211027", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001179929-21-000166-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001179929-21-000166-xbrl.zip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